Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Photoselective vaporization for prostatic obstruction with the 120‐W lithium triborate laser: 1‐year clinical outcomes

Photoselective vaporization for prostatic obstruction with the 120‐W lithium triborate laser:... There are few reports of the clinical outcomes of photoselective vaporization of the prostate (PVP) for benign prostatic hyperplasia (BPH) using the 120‐W lithium triborate (LBO) laser. The present study evaluates clinical outcomes of 76 men treated with the 120‐W LBO laser by an experienced PVP surgeon with 12 months follow up. The International Prostate Symptom Score (IPSS), peak flow rate (Qmax) and post‐void residual (PVR) were examined at baseline and at 3 and 12 months. These parameters at baseline and 12 months were 20 ± 7.0, 7.6 ± 3.5 mL/s, 155 ± 155 mL and 8.1 ± 6.1, 22.5 ± 10.3 mL/s, 59 ± 87 mL, respectively. Clinically, meaningful improvements in IPSS, Qmax and PVR were observed at 3 months and sustained at 12 months. There were few adverse events, with only 5.3% of patients requiring recatheterization. Clinical outcome at 12 months was similar to that at 3 months and to other published series. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Urology Wiley

Photoselective vaporization for prostatic obstruction with the 120‐W lithium triborate laser: 1‐year clinical outcomes

Loading next page...
 
/lp/wiley/photoselective-vaporization-for-prostatic-obstruction-with-the-120-w-buWzQzDXS1

References (11)

Publisher
Wiley
Copyright
© 2011 The Japanese Urological Association
ISSN
0919-8172
eISSN
1442-2042
DOI
10.1111/j.1442-2042.2010.02686.x
pmid
21272087
Publisher site
See Article on Publisher Site

Abstract

There are few reports of the clinical outcomes of photoselective vaporization of the prostate (PVP) for benign prostatic hyperplasia (BPH) using the 120‐W lithium triborate (LBO) laser. The present study evaluates clinical outcomes of 76 men treated with the 120‐W LBO laser by an experienced PVP surgeon with 12 months follow up. The International Prostate Symptom Score (IPSS), peak flow rate (Qmax) and post‐void residual (PVR) were examined at baseline and at 3 and 12 months. These parameters at baseline and 12 months were 20 ± 7.0, 7.6 ± 3.5 mL/s, 155 ± 155 mL and 8.1 ± 6.1, 22.5 ± 10.3 mL/s, 59 ± 87 mL, respectively. Clinically, meaningful improvements in IPSS, Qmax and PVR were observed at 3 months and sustained at 12 months. There were few adverse events, with only 5.3% of patients requiring recatheterization. Clinical outcome at 12 months was similar to that at 3 months and to other published series.

Journal

International Journal of UrologyWiley

Published: Feb 1, 2011

There are no references for this article.